These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27339590)

  • 21. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study.
    Mohamed M; Lim SC; Mumtaz M; Uppal S; Mukherjee D; Kassim MSM; Sreedharan S; Doraiswamy AM; Chong KM; Tat LY; Nordin SB; Giek JLH; Hussein Z; Kadir KA; Lau BK; Chan SP
    J ASEAN Fed Endocr Soc; 2023; 38(1):37-44. PubMed ID: 37252419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.
    Onishi Y; Ono Y; Rabøl R; Endahl L; Nakamura S
    Diabetes Obes Metab; 2013 Sep; 15(9):826-32. PubMed ID: 23557077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.
    Mehta R; Chen R; Hirose T; John M; Kok A; Lehmann R; Unnikrishnan AG; Yavuz DG; Fulcher G
    Diabetes Obes Metab; 2020 Nov; 22(11):1961-1975. PubMed ID: 32618405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan.
    Salti I;
    Diabet Med; 2009 Dec; 26(12):1255-61. PubMed ID: 20002478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design.
    Fulcher GR; Jarlov H; Piltoft JS; Singh KP; Liu L; Mohamed M; Nicodemus NA; Al-Jaser SJ; Kok A
    Endocrine; 2021 Dec; 74(3):530-537. PubMed ID: 34637072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical course of different long-acting insulin therapies-glargine U100, U300, degludec, and insulin degludec/insulin aspart-among Japanese patients with type 2 diabetes: a multicenter retrospective observational study (JDDM65 study).
    Iwamoto M; Nakanishi S; Iwamoto H; Kaneto H; Maegawa H;
    Endocr J; 2022 Jul; 69(7):763-771. PubMed ID: 35082188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical use of the co-formulation of insulin degludec and insulin aspart.
    Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
    Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ
    Diabetes Obes Metab; 2014 Mar; 16(3):193-205. PubMed ID: 23668598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting.
    Cesur M; Corapcioglu D; Gursoy A; Gonen S; Ozduman M; Emral R; Uysal AR; Tonyukuk V; Yilmaz AE; Bayram F; Kamel N
    Diabetes Res Clin Pract; 2007 Feb; 75(2):141-7. PubMed ID: 16815586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of Clinical Profile of IDegAsp.
    Unnikrishnan AG; Singh AK; Modi KD; Saboo B; Garcha SC; Rao PV
    J Assoc Physicians India; 2015 May; 63(5 Suppl):15-20. PubMed ID: 26548030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of fasting ramadan in diabetes control status - application of extensive diabetes education, serum creatinine with HbA1c statistical ANOVA and regression models to prevent hypoglycemia.
    Aziz KM
    Recent Pat Endocr Metab Immune Drug Discov; 2013 Sep; 7(3):233-51. PubMed ID: 23964680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Garber AJ; King AB; Del Prato S; Sreenan S; Balci MK; Muñoz-Torres M; Rosenstock J; Endahl LA; Francisco AM; Hollander P;
    Lancet; 2012 Apr; 379(9825):1498-507. PubMed ID: 22521072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience.
    Kisioglu SV; Demir AS; Tufekci D; Emur Gunay Y; Coskun H; Ucuncu O; Nuhoglu I; Kocak M; Karakullukcu S; Ersoz HO
    Int J Clin Pract; 2021 Sep; 75(9):e14377. PubMed ID: 34003539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of provision of optimum diabetes care on the safety of fasting in Ramadan in adult and adolescent patients with type 1 diabetes mellitus.
    Alawadi F; Alsaeed M; Bachet F; Bashier A; Abdulla K; Abuelkheir S; Rashid F; Abdulaziz Bin Hussain A; Abdelgadir E; Alsayyah F; Elsayed M; Hassanein M
    Diabetes Res Clin Pract; 2020 Nov; 169():108466. PubMed ID: 32971155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving safer Ramadan fasting by keeping flexible glycemic targets during the day and tighter targets during the night in insulin treated people with type 2 diabetes.
    Ahmedani MY; Ghafoor E
    Diabetes Res Clin Pract; 2020 Jul; 165():108234. PubMed ID: 32450103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
    Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
    Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes and Ramadan: an update on use of glycemic therapies during fasting.
    Ahmed MH; Abdu TA
    Ann Saudi Med; 2011; 31(4):402-6. PubMed ID: 21727749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attitude and safety of patients with diabetes observing the Ramadan fast.
    Ba-Essa EM; Hassanein M; Abdulrhman S; Alkhalifa M; Alsafar Z
    Diabetes Res Clin Pract; 2019 Jun; 152():177-182. PubMed ID: 30946851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
    Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.
    Jammah AA
    Prim Care Diabetes; 2021 Feb; 15(1):132-137. PubMed ID: 32839127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.